TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04069611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Subjects in the test group will take two probiotic lozenges per day for 3 months (one in the morning and one in the afternoon after brushing their teeth), starting after the last session of SRP. Lozenges will contain L. reuteri (2 x 108 colony forming units/tablet of strains ATCC 55730 and ATCC PTA 5289; Sunstar GUM Periobalance).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects assigned to the placebo group will take lozenges exactly like the test ones but without bacteria.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing
Description: Mechanical debridement with US and curettes of hard and soft plaque deposits
Study: NCT00433160

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Teriparatide
Description: daily, subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: daily, subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily, subcutaneous
Study: NCT04710355

Intervention type: DEVICE
Intervention: Spinal cord stimulation
Description: Adhesion of Intellis spinal cord stimulator to the skin of the abdomen for 4 weeks for baseline recording of activity level prior to trial with spinal cord stimulation.
Study: NCT06163183

Intervention type: DEVICE
Intervention: Edi catheter

Intervention type: DEVICE
Intervention: Edi catheter
Study: NCT02975011

Intervention type: DRUG
Intervention: Herbal medicine
Description: Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
Study: NCT01799369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surgical Apgar Score
Description: Post-operative care influenced by Surgical Apgar Score
Study: NCT02068092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxytyrosol
Study: NCT02975011

Intervention type: PROCEDURE
Intervention: Chuna manipulation
Description: Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.

Intervention type: PROCEDURE
Intervention: Bee venom pharmacopuncture
Description: Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).

Intervention type: PROCEDURE
Intervention: Pharmacopuncture
Description: Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).

Intervention type: PROCEDURE
Intervention: Acupuncture
Description: Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.

Intervention type: PROCEDURE
Intervention: Electroacupuncture
Description: Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.

Intervention type: PROCEDURE
Intervention: Cupping
Description: Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.

Intervention type: OTHER
Intervention: Other intervention(s)
Description: Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
Study: NCT01045148

Intervention type: RADIATION
Group type: OTHER
Intervention: CyberKnife Radiosurgery
Description: High Dose 3800 cGy/4 fractions

Intervention type: RADIATION
Group type: OTHER
Intervention: CyberKnife Radiosurgery
Description: Moderate Dose 3400 cGy/5 fractions
Study: NCT00075725

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IT, SC, or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IT, SC, or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT, SC, or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT, SC, or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO or IV
Study: NCT04069611

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Mechanical debridement with US and curettes of hard and soft plaque deposits
Study: NCT02998593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bahman capsules
Description: Oral Use of Bahman capsules for 3 months by patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral use of placebo capsules by patients for 3 months.
Study: NCT00075725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV
Study: NCT01011634

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous moderate sedation versus oral medication
Description: Intravenous moderate sedation (fentanyl 100 mcg and midazolam 2 mg) versus oral analgesia/anxiolysis (lorazepam 2 mg sublingual, hydrocodone/acetaminophen 5/500 mg, and ibuprofen 800 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous moderate sedation versus oral medication
Description: Intravenous moderate sedation (fentanyl 100 mcg and midazolam 2 mg) versus oral analgesia/anxiolysis (lorazepam 2 mg sublingual, hydrocodone/acetaminophen 5/500 mg, and ibuprofen 800 mg)
Study: NCT02091544

Intervention type: OTHER
Intervention: Lifestyle intervention
Study: NCT00309387

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Centrum
Description: Multivitamin/mineral supplement containing US RDA levels of nutrients. 1 tablet a day for the expected duration of follow-up (on average 10 yrs).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets manufactured to mimic Centrum tablets.
Study: NCT00560976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Saccharate (Venofer)
Description: Hemodialysis with IV iron administration of 100 mg Iron Saccharate (Venofer) in 150 ml 0.9 % saline to the arterial dialysis line during first hour of mid-week dialysis session. An alternative IV iron brand in some centers participating in the study could bebe 62.5 mg ferric gluconate (Ferrlecit).
Study: NCT02208414

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: NAET
Description: NAET with acupressure and/or chiropractic procedures with the participant holding water vial
Study: NCT00743574

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D2 (Ergocalciferol)
Description: 50,000IU (or 1 tablet), PO, monthly (supplements to be taken for three months)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone (Provera)
Description: 10mg, PO, daily for ten days
Study: NCT00888524

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GP in Physio
Description: manual therapy, educational advice of health promotion and physical exercises therapy based in a individual assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GP in Physio plus DWR
Description: GP in Physio plus a supplementation of DWR training in high intensive aerobic threshold
Study: NCT01500915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0,5mg intravitreal ranibizumab
Study: NCT02101684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orteronel 300mg BID
Study: NCT03865745

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng
Description: Take one pack of the product (3g) once a day for 24 weeks
Study: NCT03372460

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active stimulation
Description: For active tDCS, the investigators will use a 1x1 configuration with the anode placed over EEG coordinates AF7/Fp1/AF3 (using the 10-20 EEG convention) and the cathode between EEG coordinate OZ and the contralateral mastoid (covering approximately PO8/P8). The investigators will use 3x3 cm sponge covered electrodes and a 2mA current for 25 minutes per session.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: For sham tDCS, the investigators will use the same electrode and sponge configuration as active tDCS, but using the device study mode (10 µA over 15 ms current pulse applied every 550 ms, 3ms peak current).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality (VR)
Description: Participants will undergo VR exposure to trauma-related context.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Virtual Reality (VR)
Description: Participants will undergo VR exposure to trauma-related context.
Study: NCT03307161

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: osteopathic manual therapy
Description: Investigators board certified in osteopathic manual therapy will use their hands in a non-invasive manner to improve dystonia symptoms
Study: NCT01895231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside 1000 (Monofer®)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01728506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss and Exercise
Description: Internet delivered, behaviorally based weight loss and exercise intervention
Study: NCT03222973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB033 (opicinumab)
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm
Study: NCT05121220

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fixed retainer
Description: bonded lingual mandibular fixed retainer on frontal teeth 33-43

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fixed retainer
Description: bonded lingual mandibular fixed retainer on frontal teeth 33-43

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: removable retainer
Description: thermoplastic vacuum-formed removable mandibular retainer
Study: NCT00436423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine, TS-1
Study: NCT00581269

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: low-impact aerobic exercise
Description: subjects will undergo supervised physical activity for a maximum of 30-60 minutes, every other day, 3 days per week for 3 months; to offer variety in the exercise prescription, subjects will alternately use a treadmill, an elliptical trainer, a Nu-Step cross-trainer and a recumbent stationary bicycle

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low-calorie (low-fat) diet
Description: subjects will undergo a 20% reduction in total daily calories from their usual daily energy consumption every day for 3 months
Study: NCT06355947

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive cycling training
Description: Cycling training conducted with cognitive tasks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive treadmill training
Description: Treadmill training conducted with cognitive tasks
Study: NCT01854632

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SIIL Live Attenuated Influenza Vaccine
Description: Trivalent live-attenuated influenza vaccine 2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: Matched placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
Study: NCT03746600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project TRAC: Tracking and Reducing Alcohol Consumption
Description: The TRAC intervention for people living with HIV/AIDS focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage alcohol consumption. It requires eight 30-minute sessions with a counselor using videoconferencing and mobile phones. In addition to receiving the eight sessions of intervention content, participants will complete smart phone-based self-monitoring of medication adherence and alcohol consumption, which will be discussed during intervention sessions.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Project TRAC: Tracking and Reducing Alcohol Consumption
Description: The TRAC intervention for people living with HIV/AIDS focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage alcohol consumption. It requires eight 30-minute sessions with a counselor using videoconferencing and mobile phones. In addition to receiving the eight sessions of intervention content, participants will complete smart phone-based self-monitoring of medication adherence and alcohol consumption, which will be discussed during intervention sessions.
Study: NCT01069159

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol Hydrochloride
Description: The protocol of the study requires that two doses of propranolol (regular propranolol 40 mg followed two hours later by long-acting propranolol 60 mg) or placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Subjects will be randomized in a 1:1 ratio to either Propranolol treatment or placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The protocol of the study requires that two doses of placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive placebo.
Study: NCT03736993

Intervention type: OTHER
Group type: OTHER
Intervention: Additional blood sampling
Description: Establish predictive markers for early disease progression after complete surgical resection in patients with stage I to IIIA NSCLC.
Study: NCT00790868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-cycloserine
Description: 50mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 50mg
Study: NCT00743574

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (Cholecalciferol)
Description: 2,000IU (or 2 tablets), PO, daily (supplements taken for three months)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Elemental Calcium
Description: 1,000mg (or 2 tablets), PO, daily (supplements taken for three months)
Study: NCT01450436

Intervention type: OTHER
Intervention: Peapod assessment
Description: EPIPOD consists in a Non-Interventional Research according to French regulations. Actually, Peapod examination at discharge takes part of current clinical practice and patient management in Nantes Neonatal Intensive Care Unit since 2008.~After checking inclusion and non-inclusion criteria and obtaining oral informed consent from newborn legal authority or parents, PEAPOD assessment was leaded in the last week of hospitalization. Consisting in 2 repeated measurement, body composition estimation was completed by clinical and demographic data as neonatal nutrition (Parenteral nutrition pattern at Day 5, 10 and 21, and ASQ/BLR Neurodevelopmental assessment at 2 years old).
Study: NCT02483520

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: FamTechCare
Description: Caregiver submitted videos of challenging care situations are uploaded to a HIPAA secure site and reviewed by dementia care experts who provide feedback for improving care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FamTechCare
Description: Caregiver submitted videos of challenging care situations are uploaded to a HIPAA secure site and reviewed by dementia care experts who provide feedback for improving care.
Study: NCT01405599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulimorelin
Description: Single dose of 480 micrograms/kg administered as a 30 minute intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulimorelin
Description: Single dose of 480 micrograms/kg administered as a 30 minute intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulimorelin
Description: Single dose of 480 micrograms/kg administered as a 30 minute intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulimorelin
Description: Single dose of 480 micrograms/kg administered as a 30 minute intravenous infusion
Study: NCT04353076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated heatwave exposure
Description: Young and older adults (no cooling) are exposed to a 9-hour simulated exposure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated heatwave exposure
Description: Young and older adults (no cooling) are exposed to a 9-hour simulated exposure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated heatwave exposure with mid-day cooling
Description: Older adults (cooling) are exposed to a 9-hour simulated exposure with mid-day ambient cooling.
Study: NCT01102400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-575
Description: MEDI-575 will be administered weekly or every 3 weeks as IV infusion as part of a 21-day treatment cycle. One or two doses will be selected for expansion part
Study: NCT01125865

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SEMS insertion
Description: Self-expandable metallic stent will be inserted for malignant hilar obstruction.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DLS insertion
Description: DoubleLayer plastic stent will be inserted for malignant hilar obstruction.
Study: NCT06036667

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 28Fr coaxial smart drain chest tube
Description: To evaluate the efficacy of one 28Fr chest tube (coaxial smart drain versus standard chest tube according to local practice, types of drainage availability in each centre, surgeon's choice etc) after Uniportal- or Biportal-VATS upper lobectomies.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 28Fr coaxial smart drain chest tube
Description: To evaluate the efficacy of one 28Fr chest tube (coaxial smart drain versus standard chest tube according to local practice, types of drainage availability in each centre, surgeon's choice etc) after Uniportal- or Biportal-VATS upper lobectomies.
Study: NCT00193154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-774
Description: 150mg PO, days 1-28, cycle repeated every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10mg/kg, IV infusion, Days 1 and 15, 28 day cycles
Study: NCT01029795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2599506
Description: Administered orally (po), twice daily (BID) prior to morning and evening meals for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: Administered po, BID daily prior to morning and evening meals for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules administered po, BID prior to morning and evening meals for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules administered po, BID prior to morning and evening meals for 12 weeks
Study: NCT05385393

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic posterior capsulotomy of the knee
Description: The arthroscopic posterior capsulotomy of the knee is performed according to the predefined surgical technique, which was described in detail in the following publication:~Malinowski K, Góralczyk A, Hermanowicz K, LaPrade RF, Więcek R, Domżalski ME. Arthroscopic Complete Posterior Capsulotomy for Knee Flexion Contracture. Arthrosc Tech. 2018 Oct 15;7(11):e1135-e1139. doi: 10.1016/j.eats.2018.07.008. PMID: 30533360; PMCID: PMC6262078.
Study: NCT04056689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL151
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL151
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL151
Description: Oral repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral repeating dose
Study: NCT02692716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: For oral use once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: For oral use once daily.
Study: NCT05445986

Intervention type: PROCEDURE
Intervention: flap elevation and guided bone regeneration
Description: to rebuild the alveolar ridge convexity

Intervention type: PROCEDURE
Intervention: gap filling
Description: to use biomaterials to fill the jumping gap

Intervention type: PROCEDURE
Intervention: gap filling
Description: to use biomaterials to fill the jumping gap

Intervention type: PROCEDURE
Intervention: connective tissue graft
Description: to change the soft tissue phenotype by connective tissue graft

Intervention type: PROCEDURE
Intervention: connective tissue graft
Description: to change the soft tissue phenotype by connective tissue graft